Dr. Reddy’s intros Avastin biosimilar in the U.K.
Dr. Reddy’s has launched Versavo (bevacizumab) in the United Kingdom.
Dr. Reddy’s Versavo is a (bevacizumab) biosimilar of Roche’s Avastin and indicated for the treatment of several types of cancers, including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer and metastatic breast cancer.
[Read more: AAM report: Generic, biosimilar drugs generate $408B in savings]
Versavo is the first Dr. Reddy’s biosimilar product to be approved and launched in the U.K. and is available in strengths of 100 mg and 400 mg single-use vials.
Dr. Reddy’s launched Versavo in India in 2019. Subsequently, Versavo was introduced in other markets such as Thailand, Ukraine, Nepal and Jamaica under the same brand name. In Colombia, the product was launched under the brand name Persivia.
[Read more: Challenges continue, but generics companies see a bright future with biosimilars]
“The launch of Versavo in a highly regulated market underscores our capability for global clinical development of high-quality biosimilar products. Versavo is a potential treatment option for patients with different types of cancers. This launch reinforces our commitment to bring more biosimilar and other critical biological products to meet the unmet needs of patients, and strengthens our focus on oncology,” said Jayanth Sridhar, global head of biologics at Dr. Reddy’s.